In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3497-3503

  Andes, D R ^a,b   Diekema, D J ^c   Pfaller, M A ^c   Marchillo, K ^a   Bohrmueller, J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; LIPOPEPTIDES; MICE; MICE, INBRED ICR; NEUTROPENIA;

EID: 54049088997     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00478-08     Document Type: Article

References (51)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Andes, D., K. Marchillo, J. Lowther, A. Bryskier, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1187-1192.
3. Andes, D., and W. A. Craig. 2007. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 51:1633-1642.
4. Andes, D., and M. I. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis model. Antimicrob. Agents Chemother. 43:2116-2120.
5. Andes, D., and M. I. van Ogtrop. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 44:938-942.
6. Andes, D. 2001. In vivo pharmacodynamics of amphotericin B against selected Candida species. Antimicrob. Agents Chemother. 45:922-926.
7. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
8. Andes, D., K. Marchillo, J. Nett, A. Pitula, and J. Smith. 2006. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob. Agents Chemother. 50:2384-2394.
9. Andes, D., D. J. Diekema, M. A. Pfaller, R. A. Prince, K. Marchillo, J. Ashbeck, and J. Hou. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
10. Buell, D., L. Kovanda, T. Drake, et al. 2007. Alternative day dosing of micafungin in the treatment of esophageal candidiasis, abstr. M719. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
12. Clinical Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Cota, J., M. Carden, J. R. Graybill, L. K. Najvar, D. S. Burgess, and N. P. Wiederhold. 2006. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. 50:3926-3928.
14. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
15. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
16. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat. Rev. Microbiol. 2:289-300.
17. Ernst, E. J., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111.
18. Ernst, E. J., M. E. Klepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33:75-80.
19. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida subsp. Diagn. Microbiol. Infect. Dis. 26:125-131.
20. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents, and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
21. Gumbo, T., G. L. Drusano, W. Liu, R. W. Kulawy, C. Fregeau, V. Hsu, and A. Louie. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51:968-974.
22. Gumbo, T., J. Hiemenz, L. Ma, J. J. Keirns, D. N. Buell, and G. L. Drusano. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
23. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
24. Hebert, M. F., H. E. Smith, T. C. Marbury, K. S. Swan, W. B. Smith, W. S. Townsend, D. Buell, J. Keirns, and I. Bekersky. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145.
25. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
26. Louie, A., M. Deziel, W. Liu, M. F. Drusano, T. Gumbo, and G. L. Drusano. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
27. Keirns, J., T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak. 2007. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob. Agents Chemother. 51:787-790.
28. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. Dahl Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
29. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 369:1519-1527.
30. Martinez, M., and D. A. Stevens. 2006. Bioassay for azoles in the presence of caspofungin and visa versa, abstr. A2076. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
31. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.
32. Mora-Durate, J. M., R. Betts, C. Rotstein, A. Pescolombo, L. Thompson-Moya, J. S. Meitana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
33. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
34. Nakagawa, Y., Y. Ichii, Y. Saeki, M. Kodaka, K. Suzuki, and S. Kishino. 2007. Plasma concentration of micafungin in patients with hematologic malignancies. J. Infect. Chemother. 13:39-45.
35. Ota, Y., K. Tatsuno, S. Okugawa, S. Yanagimoto, T. Kitazawa, A. Fukushima, K. Tsukada, and K. Koike. 2007. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J. Infect. Chemother. 13:208-212.
36. Paderu, P., G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
37. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, W. E. Dismukes, et al. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
38. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
39. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002 Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
40. Petraitis, V., R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, C. Bacher, I. Bekersky, and T. J. Walsh. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
41. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44:3533-3538.
42. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
43. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
44. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, T. J. Walsh, et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
45. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinadli, T. J. Walsh, A. L. Barry, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
46. Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222.
47. Walsh, T. J., J. Lee, P. Kelly, J. Bacher, J. Leeciones, V. Thomas, C. L. Lyman, D. Coleman, R. Gordee, and P. A. Pizzo. 1991. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-3-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. 35:1321-1328.
48. Warn, P. A., A. Sharp, G. Morrissey, and D. W. Denning. 2002. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J. Antimicrob. Chemother. 50:1071-1074.
49. Wiederhold, N. P., L. K. Najvar, R. Bocanegra, D. Molina, M. Olivo, and J. R. Graybill. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620.
50. Wiederhold, N. P., and R. E. Lewis. 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum, and clinical efficacy. Expert Opin. Investig. Drugs 12:1313-1333.
51. Yamato, Y., H. Kanedo, T. Hashimoto, M. Katashima, K. Ishibashi, A. Kawamura, M. Terakawa, and A. Kagayama. 2002. Pharmacokinetics of the antifungal drug micafungin in mice, rats, and dogs and in its in vitro protein binding and distribution to blood cells. Jpn. J. Chemother. 50:74-79.